Iwona Rudkowska est professeure titulaire au Département de kinésiologie de la Faculté de médecine de l’Université Laval et chercheuse au Centre de recherche du CHU de Québec (Axe Endocrinologie et néphrologie). Formée en nutrition à l’Université McGill puis à l’Université Laval, elle dirige un programme de recherche dédié au développement de stratégies nutritionnelles et de nutrition de précision pour prévenir le diabète de type 2. Ses travaux portent notamment sur l’impact des différents gras alimentaires et s’appuient sur des approches de pointe telles que la métabolomique, la protéomique et l’apprentissage automatique.

Ziad Mallat received his MD and qualification in Cardiovascular Diseases from University of Pierre et Marie Curie in 1996, and his Ph.D. in Vascular Biology, Thrombosis and Haemostasis from University of Paris-Diderot in 1999. After serving as a consultant cardiologist in Versailles, he joined INSERM, Paris in 1998 and became Research Professor in 2007. He is currently the British Heart Foundation Professor of Cardiovascular Medicine at the University of Cambridge, UK. Mallat is Co-Editor of Atherosclerosis, Consulting Editor for Cardiovascular Research, and serves on the Editorial Board of JCI Insight. His work aims to understand the role of the immune system in the development and progression of cardiovascular diseases. Mallat was the first to identify a major atheroprotective role of regulatory T cells and associated anti-inflammatory cytokines, IL-10 and TGF-beta. More recently, he identified selective pathogenic and protective roles for defined B cell and innate lymphoid cell subsets in atherosclerosis and cardiac remodelling following ischemic injury. His research integrates basic discovery, pre-clinical animal studies and proof-of-concept clinical trials in coronary artery disease. Mallat was elected to the Academy of Medical Sciences, UK, for having made « sustained and internationally recognised contributions to our understanding of cardiovascular immunology and atherosclerotic disease and translated these novel findings into clinical trials and has received multiple other honour,s most recently the 2025 Lucian Award.

Vesna Todoravic joined the Nature Portfolio in 2014 as an editor for Nature Communications, handling an array of topics in development, disease, physiology and bioengineering. In 2017 she transferred to Nature, where she became responsible for content on cardiovascular biology and metabolism. She became the launch Chief Editor of Nature Cardiovascular Research in 2021. She holds a PhD in molecular biology from the University of Belgrade, Serbia, and the International Centre for Genetic Engineering and Biotechnology in Trieste, Italy, and was a research scientist at NYU Langone School of Medicine and Icahn School of Medicine at Mount Sinai in New York, where she investigated cardiovascular development and disease. Vesna is based in the Berlin office.

Guillaume Paré is a Professor of Pathology and Molecular Medicine, and a University Scholar at McMaster University. A practicing clinician-scientist, Dr. Paré completed a Master’s in Human Genetics at McGill University. He further trained in genetic epidemiology with Paul Ridker at Harvard Medical School. His clinical interests are centered on lipoprotein disorders and cardiovascular disease prevention, with research interests in cardiovascular genetics, biomarker development and pharmacogenomics. Dr. Paré’s research combines genetics, proteomics, bioinformatics and epidemiology to identify novel cardio-metabolic biomarkers. He has published over 350 original contributions in peer-reviewed journals. These include first or last authored articles in the NEJM, Lancet, Circulation, EHJ, Stroke, JACC and Nature family journals. His papers have been cited over 59,000 times with a corresponding-index of 103. Among numerous recognitions, he was inducted to the Royal Society of Canada’s College of New Scholars, Artist and Scientists in 2018.

Minna Kaikkonen‑Määttä is Professor of Cardiovascular Genomics at the University of Eastern Finland and Vice Director of Research at A.I. Virtanen Institute for Molecular Sciences. She received her PhD in Molecular Medicine from the University of Kuopio in 2008. She completed her postdoctoral training at the University of California, San Diego, specializing in transcriptional regulation and enhancer RNAs. In 2015, she established her own research group at the University of Eastern Finland, which now includes 20 researchers working across experimental and computational approaches and hosts the national Single Cell Genomics Core infrastructure. Her research investigates the genetic and cellular mechanisms underlying atherosclerosis and cardiometabolic diseases. The group uses a combination of cellular and genetic model systems, single-cell transcriptomics and epigenetics, high-throughput functional genomics, and bioinformatics to study regulatory mechanisms in vascular disease. Her work has been supported by major competitive funding, including consecutive ERC Starting and Consolidator Grants, the European Innovation Council, and the Research Council of Finland.

She has served as President of the Finnish Society of Atherosclerosis since 2021 and is an active member of the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology and the ESC Council on Cardiovascular Genomics. She has previously served on the boards of the European Vascular Biology Organization, the Scandinavian Society for Atherosclerosis Research, and the Membership Engagement Committee of the American Society of Human Genetics

Dr Simon-Pierre Guay est médecin généticien au service de génétique du département de pédiatrie du CIUSSS de l’Estrie – CHUS. Dr Guay a complété en 2014 un doctorat à l’Université de Sherbrooke sur les déterminants épigénétiques de la maladie cardiovasculaire chez les patients atteints d’hypercholestérolémie familiale. Il a par la suite effectué des études en médecine dans le programme de formation médicale à Saguenay (PFMS) de l’Université de Sherbrooke de 2014 à 2018. Il a complété sa résidence en génétique et génomique médicale à l’Université McGill en 2023 et un stage postdoctoral à la clinique de lipides, nutrition et prévention cardiovasculaire de l’Institut de recherche clinique de Montréal (IRCM) en 2024. Dr Guay est spécialisé dans le diagnostic et la prise en charge des dyslipidémies monogéniques.

Le Dr Alexis Baass est médecin biochimiste et professeur adjoint au Département de médecine (Division de médecine expérimentale) à l’Université McGill. Il est également le directeur de la Clinique des dyslipidémies génétiques de l’Institut de recherches cliniques de Montréal (IRCM), l’une des plus importantes cliniques de lipides au Canada. Cette clinique possède des activités dans tous les domaines du continuum des soins, de l’enseignement et de la recherche. Il a reçu sa certification de lipidologue du American Board of Clinical Lipidology (ABCL) et est un Fellow de la National Lipid Association (NLA). Dr Baass est également l’un des principaux auteurs (panel principal) de la plus récente prise de position de la Société canadienne de cardiologie sur l’hypercholestérolémie familiale. Ses recherches portent sur la médecine personnalisée et les dyslipidémies monogéniques (entre autres, l’hypercholestérolémie familiale, les syndromes de chylomicronémie et la dysbêtalipoprotéinémie). Il étudie les aspects biochimiques, moléculaires et pharmacologiques des dyslipidémies génétiques afin d’améliorer le dépistage, le diagnostic et le traitement de ces maladies. En 15 ans de carrière, il a publié 107 articles indexés et a participé, à titre d’investigateur principal ou de co-investigateur, à plus de 35 essais contrôlés randomisés de phases 2 et 3.

Dimitris Tsiantoulas studied molecular biology and genetics at the Democritus University of Thrace (Greece). He obtained his PhD degree from the Medical University of Vienna (Austria) in 2015, studying the functions of B cells and antibodies in atherosclerosis in Prof. Christoph Binder’s lab. He continued his training in immunity and atherosclerosis as a postdoctoral fellow, funded by the British Heart Foundation, in Prof. Ziad Mallat’s lab at the University of Cambridge. He is currently an Assoc. Prof. of Cardiovascular Immunology and a research group leader at the Medical University of Vienna. Furthermore, Dimitris has been awarded an ERC starting grant in 2023 and is a co-founder and CEO of the spin-off Aprilis pharmaceuticals.

Professor Vergès graduated in medicine from Paris University (Broussais-Hôtel Dieu) in 1986, having specialised in endocrinology, diabetes and metabolic diseases. He gained his post-doctoral fellowship at the National Institute of Health (Bethesda, USA) in Brian Brower’s laboratory, performing apolipoprotein kinetic studies using stable isotopes.

Since 1991, Professor Vergès has been Professor of Endocrinology and Diabetic Medicine at Dijon University. He also has a clinical practice in endocrinology, diabetes and lipidology at the University Hospital of Dijon and is chief of the Department of Endocrinology and Diabetes. He is also leading the research team dedicated to “Pathophysiology of dyslipidaemia in humans” in the INSERM Center UMR1231. Professor Bruno Vergès has experienced many clinical trials in the clinical department of Endocrinology, Diabetology and Lipidology at the University Hospital of Dijon and has an expertise in Lipid disorders in Diabetes and Obesity

Professor Vergès has supported with many clinical trials in the Clinical Department of Endocrinology, Diabetes and Lipidology at the University Hospital of Dijon. He was General Secretary of the French Society of Endocrinology (SFE) in 2015 and 2016 and has been president of the scientific committee of the French speaking Society for Diabetes (SFD) from March 2015 until March 2018. He is, since January 2025, president of the Francophone Foundation for the Research on Diabetes (FFRD).He has authored over 350 original publications in international journals and presented more than 630 scientific communications at national and international meetings. His has been involved in several national and international recommendations and expert consensus. His major research interests are lipid abnormalities in insulin resistance and diabetes mellitus.

Dr Pierre Corvol

Research activities and main scientific contributions: Most of my work has been focused on the hormonal control of water and salt metabolism and its effect on blood pressure and cardiovascular regulation. The renin-angiotensin aldosterone system is involved in several diseases such as high blood pressure, cardiac insufficiency, proteinuria and renal dysfunction. Major contributions of my team were : 1/ elucidation of the molecular structure and function of three major components of this system, renin, angiotensinogen and angiotensin I-converting enzyme (ACE) ; 2/ development of antibodies allowing direct assays of these parameters in biological fluids and immunohistochemistry studies ; 3/ contribution to the development of renin inhibitors and ACE inhibitors ; 4/ initiation of the first molecular genetic studies in human hypertension.

Research integrity: I have been asked in 2016 by the French minister of Higher Education and Science to conduct a  survey on scientific integrity in France. The group I assembled for this purpose  produced a report on the state of the art of scientific integrity in France and made several concrete proposals to promote or reinforce research integrity. Scientific integrity now has a legal framework. This measure is decisive and marks the transition from soft law—recommendations and codes of conduct—to binding law. I am currently working with my colleagues from the French Academy of Sciences on the ethical issues raised by the conception and the use of generative artificial intelligence in biomedical research.